Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

142
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
142
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

224
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
224
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

299
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
299
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

316
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
316
Voltage-gated Ion Channels01:26

Voltage-gated Ion Channels

7.9K
Voltage-gated ion channels are transmembrane proteins that open and close in response to changes in the membrane potential. They are present on the membranes of all electrically excitable cells such as neurons, heart, and muscle cells.
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several...
7.9K
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

367
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
367

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Kv7.2 loss-of-function causes early hyperexcitability and network remodelling.

Brain : a journal of neurology·2026
Same author

Antiseizure Medications that Did Not Reach the Epilepsy Market: An Assessment of Factors Contributing to Their Failed Clinical Development Over the Last Three Decades.

Drugs·2026
Same author

Evolution of the European Medicines Agency clinical guidelines for epilepsy drug development between 2010 and 2025: A comparative analysis by the ILAE Task Force on Regulatory Affairs.

Epilepsia·2026
Same author

Two-step voltage-sensor activation of the human K<sub>V</sub>7.4 channel and effect of a deafness-associated mutation.

Nature communications·2026
Same author

Transcription Factor Binding and Individual Genetic Risk of Valproate Teratogenicity.

Neurology·2026
Same author

Areas of research priorities in epilepsy: A position paper of the European Reference Network for Rare and Complex Epilepsies, EpiCARE.

Epilepsia open·2026

Related Experiment Video

Updated: May 31, 2025

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels
10:07

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels

Published on: January 27, 2013

15.0K

Targeting Kv7 Potassium Channels for Epilepsy.

Emilio Perucca1,2, Maurizio Taglialatela3

  • 1Department of Medicine (Austin Health), Melbourne Brain Center, The University of Melbourne, 245 Burgundy St., Heidelberg, VIC, 3084, Australia. emilio.perucca@unimelb.edu.au.

CNS Drugs
|January 24, 2025
PubMed
Summary

Voltage-gated Kv7 potassium channels are key targets for epilepsy treatment. New Kv7.2/7.3 activators like azetukalner show promise for drug-resistant seizures, offering improved safety over older medications.

More Related Videos

Patch Clamp and Perfusion Techniques for Studying Ion Channels Expressed in Xenopus oocytes
10:19

Patch Clamp and Perfusion Techniques for Studying Ion Channels Expressed in Xenopus oocytes

Published on: January 10, 2011

20.9K
Study of the Functions and Activities of Neuronal K-Cl Co-Transporter KCC2 Using Western Blotting
10:08

Study of the Functions and Activities of Neuronal K-Cl Co-Transporter KCC2 Using Western Blotting

Published on: December 9, 2022

2.1K

Related Experiment Videos

Last Updated: May 31, 2025

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels
10:07

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels

Published on: January 27, 2013

15.0K
Patch Clamp and Perfusion Techniques for Studying Ion Channels Expressed in Xenopus oocytes
10:19

Patch Clamp and Perfusion Techniques for Studying Ion Channels Expressed in Xenopus oocytes

Published on: January 10, 2011

20.9K
Study of the Functions and Activities of Neuronal K-Cl Co-Transporter KCC2 Using Western Blotting
10:08

Study of the Functions and Activities of Neuronal K-Cl Co-Transporter KCC2 Using Western Blotting

Published on: December 9, 2022

2.1K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Genetics

Background:

  • Voltage-gated Kv7 potassium channels (Kv7.2/7.3) are crucial for regulating seizure susceptibility.
  • Mutations in Kv7 channel genes lead to diverse epilepsy types.
  • Kv7.2/7.3 channel activation is a significant therapeutic target for novel antiseizure drugs.

Purpose of the Study:

  • To review the development and clinical progress of Kv7.2/7.3 channel activators as antiseizure medications.
  • To highlight novel compounds and their potential advantages over previously approved drugs.

Main Methods:

  • Review of clinical trial data and preclinical studies of Kv7.2/7.3 activators.
  • Analysis of efficacy, tolerability, and safety profiles, including adverse effects like pigmentation.
  • Examination of drug development pipelines for epilepsy and other indications.

Main Results:

  • Ezogabine (retigabine), an early Kv7.2/3 activator, was withdrawn due to safety concerns (pigmentation).
  • Azetukalner demonstrates dose-dependent efficacy in drug-resistant focal seizures with a favorable safety profile.
  • BHV-7000, pynegabine, and CB-003 are in early clinical development, with BHV-7000 showing good tolerability in Phase I.

Conclusions:

  • Interest in Kv7 channel activators for epilepsy remains high.
  • Novel Kv7.2/3 openers like azetukalner offer potential for treating drug-resistant epilepsy with improved safety.
  • Future research may focus on mechanistic differences and combination therapies for enhanced therapeutic outcomes.